2724-56-3

Basic information

• Product Name: 10-METHYLUNDECANOIC ACID
• Synonyms: ISOLAURIC ACID;JARIC I-12;10-METHYLUNDECANOIC ACID;Isoundecanoic acid
• CAS NO: 2724-56-3
• Molecular Formula: C₁₂H₂₄O₂
• Molecular Weight: 200.32
• Mol File: 2724-56-3.mol
• Article Data: 9

Chemical Properties

• Melting Point: 38-39 °C
• Boiling Point: 293.36°C (estimate)
• Flash Point: 165.7 °C
• Appearance: /Liquid
• Density: 0.8910 (rough estimate)
• Vapor Pressure: 0.000174mmHg at 25°C
• Refractive Index: 1.4251 (estimate)
• Storage Temp.: −20°C
• PKA: 4.78±0.10(Predicted)
• CAS DataBase Reference: 10-METHYLUNDECANOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 10-METHYLUNDECANOIC ACID(2724-56-3)
• EPA Substance Registry System: 10-METHYLUNDECANOIC ACID(2724-56-3)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• Hazardous Substances Data: 2724-56-3(Hazardous Substances Data)

Usage

Description

10-METHYLUNDECANOIC ACID is a methyl-branched fatty acid derived from undecanoic acid, with a methyl group substitution at the 10th position. It is a type of organic compound that belongs to the class of fatty acids and is characterized by its unique structural properties.

Uses

Used in Pharmaceutical Industry:
10-METHYLUNDECANOIC ACID is used as an active pharmaceutical ingredient for the development of various drugs. Its unique structural properties allow it to interact with specific biological targets, making it a promising candidate for the treatment of certain medical conditions.
Used in Cosmetics Industry:
10-METHYLUNDECANOIC ACID is used as an ingredient in the formulation of cosmetics and personal care products. Its fatty acid nature provides emollient and moisturizing properties, which help to improve the skin's texture and maintain its natural moisture balance.
Used in Chemical Synthesis:
10-METHYLUNDECANOIC ACID is used as a starting material or intermediate in the synthesis of various chemical compounds. Its unique structure makes it a valuable building block for the development of new molecules with potential applications in various industries, including pharmaceuticals, agrochemicals, and materials science.
Used in Research and Development:
10-METHYLUNDECANOIC ACID is used as a research tool in the study of fatty acid metabolism, biochemistry, and molecular biology. Its unique structural properties make it an interesting subject for scientific investigation, which can lead to a better understanding of biological processes and the development of new therapeutic strategies.

InChI:InChI=1/C12H24O2/c1-11(2)9-7-5-3-4-6-8-10-12(13)14/h11H,3-10H2,1-2H3,(H,13,14)

Upstream product

• 503-74-2 3-methylbutyric acid 
• 2104-19-0 azelaic monomethyl ester 
• 108040-14-8 10-methyl-9-oxo-undecanoic acid methyl ester 
• 5681-94-7 4-(5-isobutyl-thiophen-2-yl)-butyric acid 
• 92038-33-0 10-methyl-4-oxoundecanoic acid 
• 20194-45-0 10-methyl-1-undecanol 
• 626-88-0 1-bromo-5-methylpentane 
• 50530-06-8 6-bromohexanoic acid sodium salt 
• 26346-34-9 10-methylundecan-4-olide 
• 1253795-24-2 ethyl 10-methylundecanoate 
• 50530-09-1 9-bromononanoic acid sodium salt 
• 920-39-8 isopropylmagnesium bromide 
• 34386-60-2 11-hydroxy-11-methyl-dodec-1-ene 
• 106787-53-5 11-methyl-dodec-1-ene 

Downstream Products

• 6250-72-2 18-methylnonadecanoic acid 
• 20194-45-0 10-methyl-1-undecanol 
• 1086703-22-1 C₂₉H₄₇N₃O₆ 
• 1454255-90-3 C₂₃H₃₇NO₄ 
• 1004524-33-7 C₂₆H₄₂N₂O₅ 
• 1004524-53-1 C₅₂H₇₂N₆O₁₁ 

Relevant articles and documents

Carrier Protein-Free Enzymatic Biaryl Coupling in Arylomycin A2 Assembly and Structure of the Cytochrome P450 AryC**

The arylomycin antibiotics are potent inhibitors of bacterial type I signal peptidase. These lipohexapeptides contain a biaryl structural motif reminiscent of glycopeptide antibiotics. We herein describe the functional and structural evaluation of AryC, the cytochrome P450 performing biaryl coupling in biosynthetic arylomycin assembly. Unlike its enzymatic counterparts in glycopeptide biosynthesis, AryC converts free substrates without the requirement of any protein interaction partner, likely enabled by a strongly hydrophobic cavity at the surface of AryC pointing to the substrate tunnel. This activity enables chemo-enzymatic assembly of arylomycin A2 that combines the advantages of liquid- and solid-phase peptide synthesis with late-stage enzymatic cross-coupling. The reactivity of AryC is unprecedented in cytochrome P450-mediated biaryl construction in non-ribosomal peptides, in which peptidyl carrier protein (PCP)-tethering so far was shown crucial both in vivo and in vitro.

New hydroxamic acid derivative and use thereof

PROBLEM TO BE SOLVED: To provide a novel hydroxamic acid derivative having an inhibitory activity against KDM7 being a histone demethylase, and a cancer cell proliferation-suppressing action, and to provide medicines (particularly a KDM7 inhibitor and anticancer agent) using the derivative.SOLUTION: A compound represented by general formula (I) (wherein R is a linear, branched or annular alkyl group; and n is an integer of ≥6), a salt thereof, hydrate, solvate or prodrug are provided. The compound can be used as a medicine (particularly an anticancer agent) or a KDM7 inhibitor.

Identification of the KDM2/7 histone lysine demethylase subfamily inhibitor and its antiproliferative activity

Histone Nε-methyl lysine demethylases KDM2/7 have been identified as potential targets for cancer therapies. On the basis of the crystal structure of KDM7B, we designed and prepared a series of hydroxamate analogues bearing an alkyl chain. Enzyme assays revealed that compound 9 potently inhibits KDM2A, KDM7A, and KDM7B, with IC50s of 6.8, 0.2, and 1.2 μM, respectively. While inhibitors of KDM4s did not show any effect on cancer cells tested, the KDM2/7-subfamily inhibitor 9 exerted antiproliferative activity, indicating the potential for KDM2/7 inhibitors as anticancer agents.